Rapamycin works differently across tissues and ages

Rapamycin inhibits a protein called mTOR, a central cellular switch that responds to nutrients, stress, and growth signals. By suppressing mTOR, you increase autophagy: the process by which cells clear and recycle their damaged components. In mice, rapamycin reliably extends lifespan by ten to twenty percent. In humans, that evidence does not yet exist. The researchers stress in their review that mTOR is not a single target. It forms two distinct complexes, mTORC1 and mTORC2, each with different functions across different tissues.

Not all inhibition is equivalent

The problem with rapamycin is that it can affect both complexes, while the desired anti-aging effects run primarily through mTORC1. Inhibiting mTORC2 may produce unfavourable effects, including disruptions to insulin sensitivity. Moreover, the optimal level of inhibition varies by organ: what benefits the immune system is not necessarily good for muscle or heart tissue.

Age also matters. Young and old cells respond differently to mTOR inhibition. The authors argue there is room for more precise interventions that target mTORC1 more selectively, at the right time in life and in the right tissue. That is a research direction, not an available therapy.

Why human evidence is slow to arrive

A recurring issue is that rapamycin is a generic, low-cost drug. That means there are few commercial incentives to fund expensive clinical trials. The drug has potential, the authors write, but as a blunt instrument: a modest benefit at low cost is still a benefit. Nevertheless, formal human evidence is urgently needed, and it remains elusive.

Read the original article